SCHEMBL210878

SCHEMBL210878

Nc1ccccc1NC(=O)c1ccc(CC2SC(=O)NC2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
HDAC1 Q13547 15/20 0.55
HDAC3 O15379 9/20 0.53
HDAC2 Q92769 9/20 0.53
NCOR2 Q9Y618 4/20 0.53
MAPK1 P28482 1/20 0.52
PPARG P37231 2/20 0.52
NCOR1 O75376 4/20 0.52
HDAC8 Q9BY41 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209249 0.93 PPARG (0.58) MAPTHDAC1HDAC3HDAC2PPARG
SCHEMBL1079413 0.76 HDAC1 (0.55) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL12933522 0.76 HDAC1 (0.55) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL8401704 0.76 HDAC1 (0.89) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL9570559 0.76 MAPT (0.83) MAPTPPARG
SCHEMBL211677 0.75 HDAC1 (0.76) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL4715033 0.75 HDAC1 (0.70) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL210722 0.75 MAPT (0.67) MAPTPPARG
SCHEMBL211107 0.75 HDAC1 (0.70) HDAC1HDAC3HDAC2NCOR2MAPK1
SCHEMBL20333308 0.75 HDAC1 (0.60) HDAC1HDAC3HDAC2NCOR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 MAPT 3612/4885HDAC1 1/4885HDAC3 4/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 MAPT 3905/4885HDAC1 1/4885HDAC3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.